153 results about "Extracellular fluid" patented technology

A flexible mounting base to hold a sensor at an infusion site, the sensor being a removable in vivo sensor for monitoring analyte concentration level in a patient, such as blood glucose (BG) level. The mounting base comprises a flexible adhesive that anchors the flexible sensor set at an infusion site to provide stability for the sensor set in a convenient and comfortable manner. Placement of the mounting base onto the patient's skin causes the insertion needle to pierce the skin for transcutaneous placement of the cannula with the sensor therein. The insertion needle can then be withdrawn to leave the cannula and sensor at the selected insertion position, with the distal segment of the sensor being exposed to patient extracellular fluid via apertures formed in the cannula.

The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.

A method of determining an indication of the hydration status relating to a subject. The method includes determining a measured impedance value for at least one body segment, and then; for each body segment, using the measured impedance values to determine at least one indicator at least partially indicative of a level of extracellular fluid. Indicators can then be used to determine an indication of the hydration status.

The invention relates to a method and device for dialysis and or bulk fluid removal by generating a fibrosis chamber within a body cavity and performing dialysis or bulk fluid removal. An implantable medical device is described having a fibrosis chamber and a pump. A dialysis chamber and an optional electrodialysis unit can further be provided. An additional controller uses sensory feedback to regulate the fluid levels by altering the extracellular fluid retention within the fibrosis chamber. This device can be used for the treatment of patients with chronic kidney disease who may also be suffering from cardiorenal syndrome and hypertension.

In one method, one or more excitation signals with the same or different frequencies are applied to a biological object such as a tissue, simultaneously or consequently. Response signals are then cross-correlated with delayed excitation signals. Cross-correlation products are then auto-correlated. Cross-correlation products correspond to conditions of the tissue and auto-correlation product corresponds to changes in the conditions. Measuring electrical characteristics at low, intermediate and high frequency is also disclosed. At low frequency, the current flows mostly through the extracellular liquid of tissue. At high frequency, the current passes through the cell membranes freely enough to dominate the overall impedance. At both frequencies, the delay is less than 1 / 30 of the period of the respective signal. The intermediate frequency between the low frequency and the high frequency carries information about quick changes in the condition of the tissue. The delay in one example is from about 1 / 30 to ¼ of the period of the intermediate signal.

A system for measuring physiological aspects has a non-invasive monitor configured to generate monitor signals relating to fluid characteristics in the body. A computational device is operatively connected to the monitor and is configured to process the monitor signals to generate characterising data relating to at least one of regional fluid volumes, intra / extracellular fluid volume ratios and blood flow. A data output device is connected to the computational device and is configured to output the characterising data. A method and a computer program product for measuring physiological characteristics are also provided.

The invention is directed to a treatment of diseases that are accompanied by quantitative and / or qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme: said agent being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease in the average molecular weight can be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNase enzyme may be applied in a dose and regimen that provide a DNase DNA hydrolytic activity measured in blood plasma that exceeds 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.

A device for performing cell assays has at least one assay site. The site comprises a pair of stimulating electrodes and a cell confinement cavity for confining at least one cell in an extracellular fluid medium. The cell confinement cavity and the stimulating electrodes are arranged so that, in use, each cell is exposable to an electrical field generated by a potential difference applied across the stimulating electrodes. The stimulating electrodes are spaced a distance apart such that the potential difference can induce field stimulation of each cell and simultaneously be below the level that would result in electrolysis of the extracellular fluid medium.

A flexible mounting base to hold a sensor at an infusion site, the sensor being a removable in vivo sensor for monitoring analyte concentration level in a patient, such as blood glucose (BG) level. The mounting base comprises a flexible adhesive that anchors the flexible sensor set at an infusion site to provide stability for the sensor set in a convenient and comfortable manner. Placement of the mounting base onto the patient's skin causes the insertion needle to pierce the skin for transcutaneous placement of the cannula with the sensor therein. The insertion needle can then be withdrawn to leave the cannula and sensor at the selected insertion position, with the distal segment of the sensor being exposed to patient extracellular fluid via apertures formed in the cannula.

A method and apparatus for measuring changes in cell volume generally includes introducing cells into a chamber having a volume between 2 and 100 times the volume of the introduced cell. A first electrically conductive extracellular fluid is introduced into the chamber and a current is applied. The voltage induced by said current flow is measured. The first fluid is exchanged with a second electrically conductive extracellular fluid and a current is applied. The voltage induced by said current flow is measured. The first induced voltage result and the second induced voltage result are used in conjunction with known voltages induced by such current flows to monitor changes in the volume corresponding to fluid flow between the cell and an extracellular fluid.

The present invention is drawn to a method for enhancing secretional efficiency of a heterologous protein using a secretional enhancer consisting of a modified signal sequence which comprises the N-region of a signal sequence and / or a hydrophobic fragment of the said signal sequence comprising the said N-region and / or the hydrophilic polypeptide. The method of the present invention can be used not only for production of recombinant heterologous proteins by inhibiting insoluble precipitation and enhancing secretional efficiency of the recombinant protein into the periplasm or the extracellular fluid and but also for transduction of therapeutic proteins by enhancing membrane-permeability of the recombinant protein using a strong secretional enhancer.

The invention discloses bamboo fiber dissolving pulp and a production technology thereof. Bamboo is used as a material in production by using the technology, and the technology adopts the following production procedures of: preparing bamboo wood, hydrolyzing bamboo sheets in advance, performing displacement cooking of sulfate, washing and dressing in a sealing way, performing ECF (extracellular fluid) bleaching and refining, and papermaking by pulp. The displacement cooking and the ECF bleaching are used for producing the bamboo fiber dissolving pulp; a product is good in quality, high in yield, high in alpha-cellulose content, low in pentosan content, few in ashes and impurities, and even in viscosity, good in reacting property, high in whiteness, and not easy to yellow. The production of subsequent procedures is facilitated; and the bamboo fiber dissolving pulp is bleached by ClO2 without chlorine element, and the damage to the environment can be greatly reduced.

The present disclosure provides apparatuses and methods for measuring sub-epidermal moisture to provide clinicians with information related to physical conditions and ailments associated with accumulation or depletion of extracellular fluid.

The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula:R1-Cys-Phe-Gly-Arg- Arg /  - Leu /  -Asp-Arg-                    Lys    Met                                               (1)   Ile- Gly /  -Ser- Leu /  -Ser-Gly-Leu-Gly-Cys-R-2        Ser        Serwherein R1 is selected from the group consisting of:                                             (H);                                            Gly-;                                        Ser-Gly-;                                  Asp /                                   Lys /  -Ser-Gly-;                                  Gly                           Arg /    Asp /                            His /  - Lys / -Ser-Gly-;                           Gln    Gly                           Arg /    Asp /                     Met /  - His /  - Lys /  -Ser-Gly-;                    Val    Gln    Gly                           Arg /    Asp /              Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp /         Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp /     Pro-Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Gly                           Arg /    Asp / Ser-Pro-Lys- Thr /  - Met /  - His /  - Lys /  -Ser-Gly-;             Met    Val    Gln    Glyor a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof;R2 is (OH), NH2, or NR′R″ wherein R′ and R″ are independently lower alkyl (1-4C) or isAsn / LysAsn / -ValLysAsn / -Val-LeuLysAsn / -Val-Leu-ArgLysAsn / -Val-Leu-Arg- Arg / Lys                LysAsn / -Val-Leu-Arg- Arg / - Tyr / Lys                Lys    Hisor the amides (NH2 or NR′R″) thereof,with the proviso that if formula (1) isR1-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-   Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R2and R1 is Asp-Ser-Gly-, R2 cannot be Asn-Val-Leu-Arg-Arg-Tyr.The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.

The present invention discloses a method for transdermal extraction and measurement of analytes in an individual's body comprising the steps of permeabilizing the skin by electroporation in the presence of liposomes comprising negatively charged lipids, and extracting the extracellular fluid through the permeabilized skin by using suction. Analytes may be quantitated in the extracted extracellular fluid.

A method and apparatus for measuring changes in cell volume generally includes introducing cells into a chamber having a volume between 2 and 100 times the volume of the introduced cell. A first electrically conductive extracellular fluid is introduced into the chamber and a current is applied. The current flow is measured. The first fluid is exchanged with a second electrically conductive extracellular fluid and a current is applied. The current flow is measured. The first current flow result and the second current flow result are used in conjunction with known current flows to monitor changes in the volume corresponding to fluid flow between the cell and an extracellular fluid.

The estimation of the variation of the glucose level in the blood of a person by the variation of the volume of the interstitial fluid compartments in muscular tissue due to a shift of fluid between the extracellular and intracellular compartments caused by variations of the osmotic pressure of the extracellular fluids which is in turn correlated with the glucose level. The variation of the volume of the interstitial fluid compartments is detected by a non-invasive conductometry measurement using electrodes placed in contact with the skin of the person overlying a portion of soft tissue including muscular fibers. To eliminate the adverse effect of the conductivity of the capillary vessels, the conductivity of the tissue is measured independently in two directions, namely parallel and transverse to the muscular fibers.

The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.

A nanoplasmonic resonator (NPR) comprising a metallic nanodisk with alternating shielding layer(s), having a tagged biomolecule conjugated or tethered to the surface of the nanoplasmonic resonator for highly sensitive measurement of enzymatic activity. NPRs enhance Raman signals in a highly reproducible manner, enabling fast detection of protease and enzyme activity, such as Prostate Specific Antigen (paPSA), in real-time, at picomolar sensitivity levels. Experiments on extracellular fluid (ECF) from paPSA-positive cells demonstrate specific detection in a complex bio-fluid background in real-time single-step detection in very small sample volumes.

A method of determining an indication of the hydration status relating to a subject. The method includes determining a measured impedance value for at least one body segment, and then; for each body segment, using the measured impedance values to determine at least one indicator at least partially indicative of a level of extracellular fluid. Indicators can then be used to determine an indication of the hydration status.

A muscle fatigue level measuring device is provided which estimates muscle fatigue without being influenced by distances between electrodes. The muscle fatigue level measuring device measures a resistance component and a reactance component in a body part as impedance in the body part by impedance component measuring means 21, measures a muscular tissue effective length in the body part by muscular tissue effective length measuring means 22, computes biologically equivalent model parameters including extracellular fluid resistivity and distribution membrane capacitance based on these resistance component, reactance component and muscular tissue effective length by biologically equivalent model parameter computation means 23, and determines a muscle fatigue level based on the ratio of the extracellular fluid resistivity to the distribution membrane capacitance by muscle fatigue level determination means 24.

The invention discloses a bicarbonate physiological balanced solution which belongs to the field of infusion preparations and is prepared form the following raw materials: sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, glucose, citric acid and trisodium citrate. All the raw materials are accurately weighed according to corresponding portions, and dissolved in water for injection; the volume is determined; medical standard CO2 gas is introduced; the pH value is adjusted; and the solution is filtered, filled, packed, sterilized, labeled and then stored at room temperature. The solution has the advantages that ion components and a penetration concentration are similar to those of extracellular fluid and have physiological performance. The balanced solution is suitable for supplementing the extracellular fluid by injection, intravenous drip or oral administration, has an adjustment function for acid-base balance, and is also used as a surgical washing fluid or buffering solution.

The molecular formula of an anhydrous sodium acetate is C2H3NaO2; the molecular weight is 82.03; and the anhydrous sodium acetate has the following chemical structure. The preparation method is: the sodium acetate trihydrate is got and heated to be between 120 and 130 DEG C; then the sodium acetate trihydrate is decompressed and concentrated, cooled and crystallized, and dried to get the anhydrous sodium acetate. The anhydrous sodium acetate is clinically applied in the circulating blood volume, the supplement of the outer liquid of the cell when the issue liquid is reduced, and the metabolic acidosis. The advantages are: the anhydrous sodium acetate has the good solubility in water; the chemical stability is good, suitable for the human medication requirements; the anhydrous sodium acetate is easy to be stored. Because the anhydrous sodium acetate can be dissolved in water; the anhydrous sodium acetate is more suitable for the pharmaceutical preparation, in particular for the preparation of the injection. The preparation method is characterized in the high collection rate, the good product quality, the low production cost, no environmental pollution, and so on. The anhydrous sodium acetate is clinically applied in the circulating blood volume, the supplement of the outer liquid of the cell when the issue liquid is reduced, and the metabolic acidosis.

The present invention is drawn to a method for enhancing secretional efficiency of a heterologous protein using a secretional enhancer consisting of a modified signal sequence which comprises the N-region of a signal sequence and / or a hydrophobic fragment of the said signal sequence comprising the said N-region and / or the hydrophilic polypeptide. The method of the present invention can be used not only for production of recombinant heterologous proteins by inhibiting insoluble precipitation and enhancing secretional efficiency of the recombinant protein into the periplasm or the extracellular fluid and but also for transduction of therapeutic proteins by enhancing membrane-permeability of the recombinant protein using a strong secretional enhancer.

The invention discloses an intelligent human body composition scale based on double-frequency bioelectrical impedance measurement and cloud computing. The intelligent human body composition scale comprises an electronic scale detection system (10), wherein the electronic scale detection system (10) comprises a main control panel (11), a double-frequency bioelectrical impedance detection unit (12) and an electrode slice (13); the electrode slice (13) is electrically connected with the double-frequency bioelectrical impedance detection unit (12); the double-frequency bioelectrical impedance detection unit (12) is electrically connected with the main control panel (11); an electronic scale data transmission module (20) is electrically connected with the main control panel (11); the double-frequency bioelectrical impedance detection unit (12) comprises two frequency generators which are separately connected with the electrode slice (13); one frequency generator generates 500 KHz high frequency, and the other frequency generator generates 50 KHz low frequency; through the time-division measurement of human body impedance under the conditions of 500 KHz high frequency and 50 KHz low frequency, the intracellular fluid characteristic and the extracellular fluid characteristic of a human body can be fully distinguished from each other, and the correlation between the measurement result of the intelligent human body composition scale and a professional direct testing result can be remarkably improved.

We have developed a novel method of brain surface dialysis that reduces intracranial pressure and modifies movement of extracellular fluid in a rat model of brain injury. A chamber with a semipermeable membrane at the site of brain contact is perfused with a hyperosmolar solution (e.g. 15% dextran, inulin, hydroxyethyl starch). It is also capable of providing local brain cooling. In principle, osmotic forces draw water and small molecules from the injured brain into the dialysis chamber thereby reducing brain swelling. The dialysate does not move into the brain.

The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.